As a new generation of paclitaxel preparations, albumin-bound paclitaxel (albumin-paclitaxel) is a first-line drug for triple-negative breast cancer chemotherapy and occupies an extremely important position in the chemotherapy of breast cancer and other malignant tumors. This evidence concerns the gene ALB and triple-negative breast carcinoma.